董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Stacy Enxing Seng | 女 | Director | 60 | 27.52万美元 | 1.16 | 2021-11-12 |
| Mary Garrett | 女 | Director | 67 | 28.02万美元 | 0.51 | 2021-11-12 |
| Gregory J. Moore | 男 | Director | 60 | 27.52万美元 | 未持股 | 2021-11-12 |
| Felicia F. Norwood | 女 | Director | 65 | 24.50万美元 | 未持股 | 2021-11-12 |
| William H. Kucheman | 男 | Director | 75 | 27.82万美元 | 2.02 | 2021-11-12 |
| James R. Giertz | 男 | Director | 67 | 28.32万美元 | 3.33 | 2021-11-12 |
| Gary L. Ellis | 男 | Director | 68 | 29.92万美元 | 0.31 | 2021-11-12 |
| Nancy M. Schlichting | 女 | Director | 71 | 29.42万美元 | 0.48 | 2021-11-12 |
| John P. Groetelaars | 男 | President and Chief Executive Officer,Director | 55 | 762.83万美元 | 未持股 | 2021-11-12 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Deborah Rasin | 女 | Senior Vice President, Chief Legal Officer and Secretary | 55 | 205.48万美元 | 未持股 | 2021-11-12 |
| Barbara W. Bodem | 女 | Senior Vice President and Chief Financial Officer | 53 | 268.76万美元 | 未持股 | 2021-11-12 |
| Amy Dodrill | 女 | Senior Vice President and President, Surgical Solutions | 48 | 未披露 | 未持股 | 2021-11-12 |
| Mary Kay Ladone | 女 | Senior Vice President, Corporate Development, Strategy and Investor Relations | 55 | 未披露 | 未持股 | 2021-11-12 |
| Andreas G. Frank | 男 | Senior Vice President and President, Front Line Care | 45 | 216.60万美元 | 未持股 | 2021-11-12 |
| Richard M. Wagner | 男 | Vice President, Controller and Chief Accounting Officer | 53 | 未披露 | 未持股 | 2021-11-12 |
| John P. Groetelaars | 男 | President and Chief Executive Officer,Director | 55 | 762.83万美元 | 未持股 | 2021-11-12 |
| Paul Johnson | 男 | Senior Vice President and President of Patient Support Systems | 56 | 257.07万美元 | 1.19 | 2021-11-12 |
董事简历
中英对照 | 中文 | 英文- Stacy Enxing Seng
-
Stacy Enxing SengEnxing Seng女士是董事会的新提名董事。她最后担任柯惠医疗（Covidien）的驻企高管，从2012年到2014年，担任柯惠医疗的血管治疗部门的总裁；从2010年到2012年，担任外围血管部的总裁。Enxing Seng女士在柯惠医疗于2010年以26亿美元收购ev3 Incorporated后加入柯惠医疗，从2001年到2010年，她是ev3 Incorporated的创始成员，并担任执行官，负责领导ev3的外围血管部门。在这之前，她担任过SCIMED、Boston Scientific、American Hospital Supply和Baxter的职责递增的多个职位。她目前担任 Sonova Holding AG、Solace Therapeutics的董事，在这之前，担任FIRE 1 Medical Incubator和CV Ingenuity的董事。
Stacy Enxing Seng,has served as an Operating Partner with Lightstone Ventures, a venture capital group focused on medical technology and biotechnology-related investments, since 2016. Prior to joining Lightstone Ventures, Ms. Enxing Seng was with Covidien, a global healthcare products company, as its President, Vascular Therapies (2011 to 2014) and President, Peripheral Vascular (2010 to 2011). Ms. Enxing Seng joined Covidien in 2010 through the $2.6 billion acquisition of ev3 Incorporated, where she was a founding member and executive officer, responsible for leading its Peripheral Vascular division (2001 to 2010). Prior to ev3, Ms. Enxing Seng held positions of increasing responsibility with Boston Scientific, SCIMED, Baxter, and American Hospital Supply. She holds a BA in Public Policy from Michigan State University and an MBA from Harvard University. - Stacy Enxing SengEnxing Seng女士是董事会的新提名董事。她最后担任柯惠医疗（Covidien）的驻企高管，从2012年到2014年，担任柯惠医疗的血管治疗部门的总裁；从2010年到2012年，担任外围血管部的总裁。Enxing Seng女士在柯惠医疗于2010年以26亿美元收购ev3 Incorporated后加入柯惠医疗，从2001年到2010年，她是ev3 Incorporated的创始成员，并担任执行官，负责领导ev3的外围血管部门。在这之前，她担任过SCIMED、Boston Scientific、American Hospital Supply和Baxter的职责递增的多个职位。她目前担任 Sonova Holding AG、Solace Therapeutics的董事，在这之前，担任FIRE 1 Medical Incubator和CV Ingenuity的董事。
- Stacy Enxing Seng,has served as an Operating Partner with Lightstone Ventures, a venture capital group focused on medical technology and biotechnology-related investments, since 2016. Prior to joining Lightstone Ventures, Ms. Enxing Seng was with Covidien, a global healthcare products company, as its President, Vascular Therapies (2011 to 2014) and President, Peripheral Vascular (2010 to 2011). Ms. Enxing Seng joined Covidien in 2010 through the $2.6 billion acquisition of ev3 Incorporated, where she was a founding member and executive officer, responsible for leading its Peripheral Vascular division (2001 to 2010). Prior to ev3, Ms. Enxing Seng held positions of increasing responsibility with Boston Scientific, SCIMED, Baxter, and American Hospital Supply. She holds a BA in Public Policy from Michigan State University and an MBA from Harvard University.
- Mary Garrett
-
Mary Garrett，曾担任IBM Global Sales and Distribution的副总裁，负责营销和沟通，领导地理营销团队、行业全球营销、企业和中型企业业务设计、数码销售和现场支持。此外，她曾担任IBM的咨询委员会的秘书，在那里她推动IBM全球最大的在线学术交流协会的对话，也曾担任the CMO Council的秘书，在那里她促进与世界领先的营销人员的最佳实践交流。此前，她曾领导IBM Global Technology Services的全球营销。她任职于the American Marketing Association（全球专业协会，拥有30000多名成员）的董事会，在那里她也担任财务副总裁兼秘书。她也是美国W.O.M.E.N。（专业开发团队，旨在提升有前途的职业女性）的活跃导师。
Mary Garrett,has served as a director of Omnicell since May 2022. Ms. Garrett is currently the President of M. Power Coaching and Consulting, LLC, a firm focused on developing executive leaders and helping organizations align brand and culture, customer experience and employee engagement for positive impact on business vitality and growth. Ms. Garrett has held this position since June 2018. From September 2008 until December 2015, Ms. Garrett served as the chief marketing officer, global markets at International Business Machines Corporation ("IBM"), a leading global provider of technology products and services. Prior to that, Ms. Garrett served in key positions of increasing authority and responsibility upon joining IBM in 1981 through August 2008. Ms. Garrett currently serves as a director of PROCEPT BioRobotics Corp., a surgical robotics company, and has served on the board of this company and as chair of its nominating and governance committee since December 2021. Ms. Garrett previously served as a director of Ethan Allen Interiors, Inc., a leading interior design company, manufacturer and retailer in the home furnishings marketplace, from January 2016 until November 2021, and was a member of the Audit Committee. She has also served as a director of Hillrom Corporation (subsequently acquired by Baxter International, Inc.), a global medical technology company, from March 2017 until December 2021, and was chair of the Nominating/Corporate Governance Committee and a member of the Audit Committee. Ms. Garrett received a B.S. in bio-medical engineering from Brown University and an M.S. in bio-electrical engineering from Brown University. - Mary Garrett，曾担任IBM Global Sales and Distribution的副总裁，负责营销和沟通，领导地理营销团队、行业全球营销、企业和中型企业业务设计、数码销售和现场支持。此外，她曾担任IBM的咨询委员会的秘书，在那里她推动IBM全球最大的在线学术交流协会的对话，也曾担任the CMO Council的秘书，在那里她促进与世界领先的营销人员的最佳实践交流。此前，她曾领导IBM Global Technology Services的全球营销。她任职于the American Marketing Association（全球专业协会，拥有30000多名成员）的董事会，在那里她也担任财务副总裁兼秘书。她也是美国W.O.M.E.N。（专业开发团队，旨在提升有前途的职业女性）的活跃导师。
- Mary Garrett,has served as a director of Omnicell since May 2022. Ms. Garrett is currently the President of M. Power Coaching and Consulting, LLC, a firm focused on developing executive leaders and helping organizations align brand and culture, customer experience and employee engagement for positive impact on business vitality and growth. Ms. Garrett has held this position since June 2018. From September 2008 until December 2015, Ms. Garrett served as the chief marketing officer, global markets at International Business Machines Corporation ("IBM"), a leading global provider of technology products and services. Prior to that, Ms. Garrett served in key positions of increasing authority and responsibility upon joining IBM in 1981 through August 2008. Ms. Garrett currently serves as a director of PROCEPT BioRobotics Corp., a surgical robotics company, and has served on the board of this company and as chair of its nominating and governance committee since December 2021. Ms. Garrett previously served as a director of Ethan Allen Interiors, Inc., a leading interior design company, manufacturer and retailer in the home furnishings marketplace, from January 2016 until November 2021, and was a member of the Audit Committee. She has also served as a director of Hillrom Corporation (subsequently acquired by Baxter International, Inc.), a global medical technology company, from March 2017 until December 2021, and was chair of the Nominating/Corporate Governance Committee and a member of the Audit Committee. Ms. Garrett received a B.S. in bio-medical engineering from Brown University and an M.S. in bio-electrical engineering from Brown University.
- Gregory J. Moore
-
Gregory J. Moore，自 2019 年以来一直担任微软公司“微软”的公司副总裁，是一家生产计算机软件、云计算服务、个人计算机和电子产品以及其他相关服务的跨国技术公司，他领导着微软公司的健康和生活科学研究和产品开发组合。在加入微软之前，Moore博士于 2016 年至 2019 年担任谷歌公司副总裁，微软公司是一家专门从事互联网相关产品和服务的跨国科技公司，并且是全球谷歌云医疗保健和生命科学的创始人和领导者。 Moore 博士是一名工程师、执业医师和经验丰富的教育家。他在诊断放射学、神经放射学和临床信息学方面获得了委员会认证。在担任 Microsoft 和 Google 的领导职务之前，Moore 博士曾担任地区医疗保健提供商 Geisinger Health System 的首席新兴技术和信息学官，同时他还担任高级应用研究所所长。他之前的学术和临床任命包括斯坦福大学医学院、宾夕法尼亚州立大学医学院和韦恩州立大学医学院。从 2019 年到 2021 年与 Baxter International Inc. 合并，Moore 博士一直是医疗技术提供商 Hill-Rom Holdings, Inc. 的董事会成员。
Gregory J. Moore,served as Corporate Vice President for Microsoft Health and Life Sciences, a division of Microsoft Corporation ("Microsoft"), a multinational technology company that produces computer software, cloud computing services, personal computers and electronics, and other related services, from 2019 to 2023, where he led Microsoft's health and life sciences research and artificial intelligence ("AI") and cloud product development portfolio. Prior to Microsoft, Dr. Moore served as Vice President of Google Inc. ("Google"), a multinational technology company that specializes in Internet-related products and services, from 2016 to 2019, and was the founder and leader of Google Cloud Healthcare and Life Sciences globally. Dr. Moore is an engineer, practicing physician, and experienced educator. He is board certified in Diagnostic Radiology, Neuroradiology and Clinical Informatics. Prior to his leadership roles at Microsoft and Google, Dr. Moore served as the Chief Emerging Technology and Informatics Officer at Geisinger Health System, a regional healthcare provider, where he was also Director of the Institute of Advanced Application. His prior academic and clinical appointments include Stanford University School of Medicine, Penn State University College of Medicine, and Wayne State University School of Medicine. In February 2025, Dr. Moore was appointed as a member of the Board of Directors of Fortive Corporation, a provider of essential technologies for connected workflow solutions. From 2023 to 2024, Dr. Moore served as a member of the Board of Directors of Olink Holding AB, a biotechnology company focused on proteomics, until its merger with Thermo Fisher Scientific Inc., and from 2019 to 2021, Dr. Moore served as a director of Hill-Rom Holdings, Inc., a medical technology provider, until its merger with Baxter International Inc. In 2024, Dr. Moore earned the National Association of Corporate Directors ("NACD") CERT Certificate in Cyber-Risk Oversight. - Gregory J. Moore，自 2019 年以来一直担任微软公司“微软”的公司副总裁，是一家生产计算机软件、云计算服务、个人计算机和电子产品以及其他相关服务的跨国技术公司，他领导着微软公司的健康和生活科学研究和产品开发组合。在加入微软之前，Moore博士于 2016 年至 2019 年担任谷歌公司副总裁，微软公司是一家专门从事互联网相关产品和服务的跨国科技公司，并且是全球谷歌云医疗保健和生命科学的创始人和领导者。 Moore 博士是一名工程师、执业医师和经验丰富的教育家。他在诊断放射学、神经放射学和临床信息学方面获得了委员会认证。在担任 Microsoft 和 Google 的领导职务之前，Moore 博士曾担任地区医疗保健提供商 Geisinger Health System 的首席新兴技术和信息学官，同时他还担任高级应用研究所所长。他之前的学术和临床任命包括斯坦福大学医学院、宾夕法尼亚州立大学医学院和韦恩州立大学医学院。从 2019 年到 2021 年与 Baxter International Inc. 合并，Moore 博士一直是医疗技术提供商 Hill-Rom Holdings, Inc. 的董事会成员。
- Gregory J. Moore,served as Corporate Vice President for Microsoft Health and Life Sciences, a division of Microsoft Corporation ("Microsoft"), a multinational technology company that produces computer software, cloud computing services, personal computers and electronics, and other related services, from 2019 to 2023, where he led Microsoft's health and life sciences research and artificial intelligence ("AI") and cloud product development portfolio. Prior to Microsoft, Dr. Moore served as Vice President of Google Inc. ("Google"), a multinational technology company that specializes in Internet-related products and services, from 2016 to 2019, and was the founder and leader of Google Cloud Healthcare and Life Sciences globally. Dr. Moore is an engineer, practicing physician, and experienced educator. He is board certified in Diagnostic Radiology, Neuroradiology and Clinical Informatics. Prior to his leadership roles at Microsoft and Google, Dr. Moore served as the Chief Emerging Technology and Informatics Officer at Geisinger Health System, a regional healthcare provider, where he was also Director of the Institute of Advanced Application. His prior academic and clinical appointments include Stanford University School of Medicine, Penn State University College of Medicine, and Wayne State University School of Medicine. In February 2025, Dr. Moore was appointed as a member of the Board of Directors of Fortive Corporation, a provider of essential technologies for connected workflow solutions. From 2023 to 2024, Dr. Moore served as a member of the Board of Directors of Olink Holding AB, a biotechnology company focused on proteomics, until its merger with Thermo Fisher Scientific Inc., and from 2019 to 2021, Dr. Moore served as a director of Hill-Rom Holdings, Inc., a medical technology provider, until its merger with Baxter International Inc. In 2024, Dr. Moore earned the National Association of Corporate Directors ("NACD") CERT Certificate in Cyber-Risk Oversight.
- Felicia F. Norwood
-
Felicia F. Norwood，伊利诺伊州医疗保健和家庭服务部主任（2015 - 2018年）。1994年至2013年在Aetna公司担任各种高级职务。
Felicia F. Norwood,is an accomplished healthcare executive currently serving as EVP and President of Government Health Benefits at Elevance Health (since 2018), where she oversees Medicare/Medicaid strategy and operations. Norwood offers deep expertise in risk management within highly regulated environments, strategic planning for government health programs, and human capital leadership across complex healthcare systems. - Felicia F. Norwood，伊利诺伊州医疗保健和家庭服务部主任（2015 - 2018年）。1994年至2013年在Aetna公司担任各种高级职务。
- Felicia F. Norwood,is an accomplished healthcare executive currently serving as EVP and President of Government Health Benefits at Elevance Health (since 2018), where she oversees Medicare/Medicaid strategy and operations. Norwood offers deep expertise in risk management within highly regulated environments, strategic planning for government health programs, and human capital leadership across complex healthcare systems.
- William H. Kucheman
-
自2011年10月起，William H. Kucheman一直是我们的首席执行官和董事。从2010年2月至任现职，他担任执行副总裁兼总裁以及任Cardiology, Rhythm 和 Vascular Group的总裁。 从2006年11月至2010年2月，他是我们的高级副总裁兼心血管组总裁。在此之前，从2001年6月至2006年11月，他是市场营销的高级副总裁。在该职位上，他负责我们的心血管组全球营销职能和所有企业营销的职能。他负责监督TAXUS paclitaxel-eluting coronary stent system商业化战略，定义和发展我们的偿还和成果规划职责，并首创营销科学和电子营销计划。在此之前，1995年2月至2001年6月，他是我们企业营销部副总裁和公司副总裁。他于1995年加入我公司，战略营销作为我们收购SCIMED Life Systems的成果。在1995年之前，他担任过SCIMED ，Charter Medical 公司和 Control Data公司多个销售和营销职位。他 在美国的空军学院医院开始了他的职业生涯，其后是任 美国的空军医疗服务 外科总医师的办公室保健规划师。他曾在多个行业的委员会任职，包括 Global Healthcare Exchange, the Committee on Payment and Policy 和 AdvaMed。他获得弗吉尼亚理工学院学士学位和工商管理硕士学位。
William H. Kucheman has served as a director of Hillrom since 2013. He previously served as interim Chief Executive Officer for Boston Scientific Corporation, a manufacturer of medical devices, from September 2011 until his retirement in November 2012. Before being named interim CEO, he was Executive Vice President and President of the Cardiology, Rhythm and Vascular CRV Group of Boston Scientific. He joined the company in 1995 as a result of Boston Scientific's acquisition of SCIMED Life Systems, Inc., becoming Senior Vice President of Marketing. In this role, Mr. Kucheman was responsible for global marketing. He has served on several industry boards, including the board of directors of the Global Health Exchange and on the boards of several non-public companies. - 自2011年10月起，William H. Kucheman一直是我们的首席执行官和董事。从2010年2月至任现职，他担任执行副总裁兼总裁以及任Cardiology, Rhythm 和 Vascular Group的总裁。 从2006年11月至2010年2月，他是我们的高级副总裁兼心血管组总裁。在此之前，从2001年6月至2006年11月，他是市场营销的高级副总裁。在该职位上，他负责我们的心血管组全球营销职能和所有企业营销的职能。他负责监督TAXUS paclitaxel-eluting coronary stent system商业化战略，定义和发展我们的偿还和成果规划职责，并首创营销科学和电子营销计划。在此之前，1995年2月至2001年6月，他是我们企业营销部副总裁和公司副总裁。他于1995年加入我公司，战略营销作为我们收购SCIMED Life Systems的成果。在1995年之前，他担任过SCIMED ，Charter Medical 公司和 Control Data公司多个销售和营销职位。他 在美国的空军学院医院开始了他的职业生涯，其后是任 美国的空军医疗服务 外科总医师的办公室保健规划师。他曾在多个行业的委员会任职，包括 Global Healthcare Exchange, the Committee on Payment and Policy 和 AdvaMed。他获得弗吉尼亚理工学院学士学位和工商管理硕士学位。
- William H. Kucheman has served as a director of Hillrom since 2013. He previously served as interim Chief Executive Officer for Boston Scientific Corporation, a manufacturer of medical devices, from September 2011 until his retirement in November 2012. Before being named interim CEO, he was Executive Vice President and President of the Cardiology, Rhythm and Vascular CRV Group of Boston Scientific. He joined the company in 1995 as a result of Boston Scientific's acquisition of SCIMED Life Systems, Inc., becoming Senior Vice President of Marketing. In this role, Mr. Kucheman was responsible for global marketing. He has served on several industry boards, including the board of directors of the Global Health Exchange and on the boards of several non-public companies.
- James R. Giertz
-
自2009年以来，James R. Giertz一直担任Hill-Rom 的董事。2008年3月以来，他一直任H.B. Fuller 公司高级副总裁兼首席财务官，公司位于明尼苏达州圣保罗。加盟H.B. Fuller 前，在2007年连续数月他担任Residential Capital, LLC的高级运营总监，首席财务官，以及董事，住宅投资有限责任公司，这是美国最大的房屋贷款发起人，服务商和证券商之一。在此之前，他是Donaldson 公司 工业产品事业部高级副总裁兼公司首席财务官，这是一家过滤系统及更换部件的全球供应商。此外，他担任General Motors母公司的助理财务总监，并曾于加拿大和欧洲任多个国际财政职位。他还担任了美国中上西北地区青年成就组织的董事。 他在编制财务报表，会计和经营方面以及在大型企业任高级官员的经验为董事会带来知识和宝贵的见解。此外，他的国际经验对 Boar也是一笔宝贵的财富。
James R. Giertz has served as a director of Hillrom since 2009. He served as the Senior Vice President and Chief Financial Officer of H.B. Fuller Company, St. Paul, Minnesota, an adhesives manufacturing company, from March 2008 until his retirement in February 2017. Prior to joining H.B. Fuller, he served as Senior Managing Director, Chief Financial Officer and, for several months in 2007 a director, of Residential Capital, LLC, one of the largest originators, servicers and securitizers of home loans in the United States. Prior to that, he was Senior Vice President of the Industrial Products division, and Chief Financial Officer of Donaldson Company, Inc., a worldwide provider of filtration systems and replacement parts. In addition, Mr. Giertz served as assistant treasurer of the parent company at General Motors, and also held several international treasury positions in Canada and Europe. Mr. Giertz currently serves as a director of Schneider National, Inc. and Chairs the Audit Committee. - 自2009年以来，James R. Giertz一直担任Hill-Rom 的董事。2008年3月以来，他一直任H.B. Fuller 公司高级副总裁兼首席财务官，公司位于明尼苏达州圣保罗。加盟H.B. Fuller 前，在2007年连续数月他担任Residential Capital, LLC的高级运营总监，首席财务官，以及董事，住宅投资有限责任公司，这是美国最大的房屋贷款发起人，服务商和证券商之一。在此之前，他是Donaldson 公司 工业产品事业部高级副总裁兼公司首席财务官，这是一家过滤系统及更换部件的全球供应商。此外，他担任General Motors母公司的助理财务总监，并曾于加拿大和欧洲任多个国际财政职位。他还担任了美国中上西北地区青年成就组织的董事。 他在编制财务报表，会计和经营方面以及在大型企业任高级官员的经验为董事会带来知识和宝贵的见解。此外，他的国际经验对 Boar也是一笔宝贵的财富。
- James R. Giertz has served as a director of Hillrom since 2009. He served as the Senior Vice President and Chief Financial Officer of H.B. Fuller Company, St. Paul, Minnesota, an adhesives manufacturing company, from March 2008 until his retirement in February 2017. Prior to joining H.B. Fuller, he served as Senior Managing Director, Chief Financial Officer and, for several months in 2007 a director, of Residential Capital, LLC, one of the largest originators, servicers and securitizers of home loans in the United States. Prior to that, he was Senior Vice President of the Industrial Products division, and Chief Financial Officer of Donaldson Company, Inc., a worldwide provider of filtration systems and replacement parts. In addition, Mr. Giertz served as assistant treasurer of the parent company at General Motors, and also held several international treasury positions in Canada and Europe. Mr. Giertz currently serves as a director of Schneider National, Inc. and Chairs the Audit Committee.
- Gary L. Ellis
-
Gary L. Ellis，是美敦力公司的高级副总裁兼首席财务官，这是一家位于明尼苏达州明尼阿波利斯的全球医疗技术公司。自2005年5月以来，他一直曾担任这些职务。此前，从1999年至2005年5月，他是美敦力公司的副总裁、公司主管及财务总监。在2006年，他首次当选为托罗董事会。他是财务委员会的主席和审计委员会的成员。他任职于美国明尼苏达科学博物馆和大双城联合劝募组织的董事。
Gary L. Ellis,retired from Medtronic plc, Dublin, Ireland (a global medical technology company). He held the following positions, all at Medtronic:Executive Vice President, Global Operations, Information Technology and Facilities & Real Estate (June 2016 – December 2016).Executive Vice President and Chief Financial Officer (April 2014 – June 2016).Senior Vice President and Chief Financial Officer (May 2005 – April 2014).Vice President, Corporate Controller and Treasurer (October 1999 – May 2005). - Gary L. Ellis，是美敦力公司的高级副总裁兼首席财务官，这是一家位于明尼苏达州明尼阿波利斯的全球医疗技术公司。自2005年5月以来，他一直曾担任这些职务。此前，从1999年至2005年5月，他是美敦力公司的副总裁、公司主管及财务总监。在2006年，他首次当选为托罗董事会。他是财务委员会的主席和审计委员会的成员。他任职于美国明尼苏达科学博物馆和大双城联合劝募组织的董事。
- Gary L. Ellis,retired from Medtronic plc, Dublin, Ireland (a global medical technology company). He held the following positions, all at Medtronic:Executive Vice President, Global Operations, Information Technology and Facilities & Real Estate (June 2016 – December 2016).Executive Vice President and Chief Financial Officer (April 2014 – June 2016).Senior Vice President and Chief Financial Officer (May 2005 – April 2014).Vice President, Corporate Controller and Treasurer (October 1999 – May 2005).
- Nancy M. Schlichting
-
Nancy M. Schlichting在Baxter收购Hillrom后加入董事会，她此前曾担任董事兼薪酬和管理发展委员会主席。Schlichting女士是密歇根州底特律Henry Ford Health System（HFHS）的退休总裁兼首席执行官，Henry Ford Health System是一家非营利性医疗保健组织，于2003年6月至2017年1月担任该职务。她于1998年加入HFHS，担任高级副总裁兼首席行政官，1999年至2003年晋升为执行副总裁兼首席运营官，2001年至2003年晋升为Henry Ford医院总裁兼首席执行官。她目前担任Walgreens Boots Alliance和Encompass Health, Inc.的董事，并担任杜克大学受托人和杜克大学健康系统董事会主席。她此前曾担任Pear Therapeutics，Inc.的董事和Kresge基金会的受托人。
Nancy M. Schlichting,joined the Board in 2021 following Baxter's acquisition of Hill-Rom Holdings, Inc. (Hillrom), where she had previously served as a director and Chair of its Compensation and Management Development Committee. Ms. Schlichting is the retired President and Chief Executive Officer of Henry Ford Health System (HFHS) in Detroit, Michigan, a non-profit healthcare organization, serving in this role from June 2003 to January 2017. She joined HFHS in 1998 as Senior Vice President and Chief Administrative Officer and served as Executive Vice President and Chief Operating Officer from 1999 to 2003 and as President and Chief Executive Officer of Henry Ford Hospital from 2001 to 2003. She currently serves as a director of Encompass Health, Inc. and Walgreens Boots Alliance, and as a trustee of the Duke University and as the chair of the Duke University Health System Board. She previously served as a director of Pear Therapeutics, Inc. and as a trustee of the Kresge Foundation. - Nancy M. Schlichting在Baxter收购Hillrom后加入董事会，她此前曾担任董事兼薪酬和管理发展委员会主席。Schlichting女士是密歇根州底特律Henry Ford Health System（HFHS）的退休总裁兼首席执行官，Henry Ford Health System是一家非营利性医疗保健组织，于2003年6月至2017年1月担任该职务。她于1998年加入HFHS，担任高级副总裁兼首席行政官，1999年至2003年晋升为执行副总裁兼首席运营官，2001年至2003年晋升为Henry Ford医院总裁兼首席执行官。她目前担任Walgreens Boots Alliance和Encompass Health, Inc.的董事，并担任杜克大学受托人和杜克大学健康系统董事会主席。她此前曾担任Pear Therapeutics，Inc.的董事和Kresge基金会的受托人。
- Nancy M. Schlichting,joined the Board in 2021 following Baxter's acquisition of Hill-Rom Holdings, Inc. (Hillrom), where she had previously served as a director and Chair of its Compensation and Management Development Committee. Ms. Schlichting is the retired President and Chief Executive Officer of Henry Ford Health System (HFHS) in Detroit, Michigan, a non-profit healthcare organization, serving in this role from June 2003 to January 2017. She joined HFHS in 1998 as Senior Vice President and Chief Administrative Officer and served as Executive Vice President and Chief Operating Officer from 1999 to 2003 and as President and Chief Executive Officer of Henry Ford Hospital from 2001 to 2003. She currently serves as a director of Encompass Health, Inc. and Walgreens Boots Alliance, and as a trustee of the Duke University and as the chair of the Duke University Health System Board. She previously served as a director of Pear Therapeutics, Inc. and as a trustee of the Kresge Foundation.
- John P. Groetelaars
-
John P. Groetelaars在2008年加入 Bard 在Davol部门担任副总裁和总经理。在2009年Mr. Groetelaars 被提名为Davol部总裁。在2013年七月，Mr. Groetelaars晋升为集团副总裁和负责中国、亚洲、澳大利亚的特别小组，继续负责 Bards Davol部门。在加入Bard之前，他担任了多种职务，包括从2001年至加入Bard公司之前负责波士顿科学公司事务，在英国、爱尔兰和北欧地区担任总经理和副总裁。
John P. Groetelaars served as President & Chief Executive Officer and as a director of Hill-Rom Holdings, Inc. from May 14 2018 until the company’s acquisition by Baxter International, Inc. in December 2021. At Hillrom, Mr. Groetelaars had enterprise responsibility for a global healthcare technology company with $3 billion in revenue and more than 10000 employees. Mr. Groetelaars led a transformation of Hillrom’s business, successfully articulating and launching a new connected-care strategy and vision, growing the portfolio through seven acquisitions and one divestiture, and driving record financial performance. In addition, he championed and actively led diversity, inclusion, equity and belonging initiatives across the company, which led to record levels of employee engagement, and external recognition from DiversityInc, Forbes and many other organizations. Prior to Hill-Rom, Mr. Groetelaars served as executive vice president and president of the Interventional Segment at Becton, Dickinson and Company, a medical technology company, since December 2017 following its acquisition of C.R. Bard Inc., a medical technology company, where his responsibilities included global strategic, financial, operational and innovation platforms. He previously served in a variety of progressive roles at C.R. Bard during his 10-year career there, including as a group president from 2015 to 2017. Mr. Groetelaars joined C.R. Bard in 2008 as vice president and general manager, Davol Inc., and was appointed president of Davol in 2009. In 2013 Mr. Groetelaars was promoted to group vice president and in 2015 he was promoted to group president, a position he held until C.R. Bard was acquired by Becton, Dickinson and Company in December 2017. Prior to joining C.R. Bard, Mr. Groetelaars held various international leadership positions in Canada, Denmark and the United Kingdom at Boston Scientific Corporation from 2001 until 2008. Prior to joining Boston Scientific, Mr. Groetelaars held positions in general management, marketing, business development and sales with Guidant Corporation and with Eli Lilly. He was also formerly a director on the AdvaMed board. - John P. Groetelaars在2008年加入 Bard 在Davol部门担任副总裁和总经理。在2009年Mr. Groetelaars 被提名为Davol部总裁。在2013年七月，Mr. Groetelaars晋升为集团副总裁和负责中国、亚洲、澳大利亚的特别小组，继续负责 Bards Davol部门。在加入Bard之前，他担任了多种职务，包括从2001年至加入Bard公司之前负责波士顿科学公司事务，在英国、爱尔兰和北欧地区担任总经理和副总裁。
- John P. Groetelaars served as President & Chief Executive Officer and as a director of Hill-Rom Holdings, Inc. from May 14 2018 until the company’s acquisition by Baxter International, Inc. in December 2021. At Hillrom, Mr. Groetelaars had enterprise responsibility for a global healthcare technology company with $3 billion in revenue and more than 10000 employees. Mr. Groetelaars led a transformation of Hillrom’s business, successfully articulating and launching a new connected-care strategy and vision, growing the portfolio through seven acquisitions and one divestiture, and driving record financial performance. In addition, he championed and actively led diversity, inclusion, equity and belonging initiatives across the company, which led to record levels of employee engagement, and external recognition from DiversityInc, Forbes and many other organizations. Prior to Hill-Rom, Mr. Groetelaars served as executive vice president and president of the Interventional Segment at Becton, Dickinson and Company, a medical technology company, since December 2017 following its acquisition of C.R. Bard Inc., a medical technology company, where his responsibilities included global strategic, financial, operational and innovation platforms. He previously served in a variety of progressive roles at C.R. Bard during his 10-year career there, including as a group president from 2015 to 2017. Mr. Groetelaars joined C.R. Bard in 2008 as vice president and general manager, Davol Inc., and was appointed president of Davol in 2009. In 2013 Mr. Groetelaars was promoted to group vice president and in 2015 he was promoted to group president, a position he held until C.R. Bard was acquired by Becton, Dickinson and Company in December 2017. Prior to joining C.R. Bard, Mr. Groetelaars held various international leadership positions in Canada, Denmark and the United Kingdom at Boston Scientific Corporation from 2001 until 2008. Prior to joining Boston Scientific, Mr. Groetelaars held positions in general management, marketing, business development and sales with Guidant Corporation and with Eli Lilly. He was also formerly a director on the AdvaMed board.
高管简历
中英对照 | 中文 | 英文- Deborah Rasin
Deborah Rasin，于2016年1月当选Hill-Rom公司的高级副总裁、首席法务官和秘书。此前，她曾担任Dentsply Sirona, Inc的总法律顾问。任职Dentsply公司之前，她曾担任Samsonite Corporation的总法律顾问，任职丹佛和伦敦，也担任GM（位于底特律和苏黎世）的高级律师。
Deborah Rasin, was elected Senior Vice President, Chief Legal Officer and Secretary, effective January 2016. Before joining Hillrom, she was General Counsel for Dentsply International Inc. Previously, she served as General Counsel at Samsonite Corporation and as a senior attorney at General Motors.- Deborah Rasin，于2016年1月当选Hill-Rom公司的高级副总裁、首席法务官和秘书。此前，她曾担任Dentsply Sirona, Inc的总法律顾问。任职Dentsply公司之前，她曾担任Samsonite Corporation的总法律顾问，任职丹佛和伦敦，也担任GM（位于底特律和苏黎世）的高级律师。
- Deborah Rasin, was elected Senior Vice President, Chief Legal Officer and Secretary, effective January 2016. Before joining Hillrom, she was General Counsel for Dentsply International Inc. Previously, she served as General Counsel at Samsonite Corporation and as a senior attorney at General Motors.
- Barbara W. Bodem
BarbaraW.Bodem高级副总裁和首席财务官当选，自2018年12月起生效。加入Hillrom公司之前，她曾担任Mallinckrodt公司的高级副总裁，财务。此前，她曾担任好比拉医疗保健公司和礼来公司（Eli Lilly）的多种高级财务职务，包括礼来肿瘤公司的首席财务官。
Barbara W. Bodem,was interim Chief Financial Officer of Dentsply Sirona Inc., a public dental equipment and supplies manufacturing company, from April 2022 to October 2022. Prior to that, she served as Senior Vice President and Chief Financial Officer of Hill-Rom Holdings, Inc., a medical device and medical technology provider, from 2018 until its acquisition by Baxter International Inc. in 2021. Earlier in her career, she served as Senior Vice President of Finance of Mallinckrodt Pharmaceuticals, a pharmaceutical manufacturer, from 2015 to 2018. She previously served in senior finance roles at Hospira, Inc. and Eli Lilly and Company.Ms. Bodem currently serves on the boards of Enovis Corp., a public medical technology company, and Option Care Health, Inc., a public provider of home and alternate site infusion services. She also serves on the boards of BiomEdit LLC, a private animal health company, NorthStar Medical Radioisotopes, a radiopharmaceutical company and the non-profit Nature Conservancy of Indiana. In the past five years, Ms. Bodem served on the boards of Syneos Health, Inc. and Turning Point Therapeutics, Inc. She also served on the board of Invacare Corporation.She holds a B.S. in Finance and an M.B.A from Indiana University.- BarbaraW.Bodem高级副总裁和首席财务官当选，自2018年12月起生效。加入Hillrom公司之前，她曾担任Mallinckrodt公司的高级副总裁，财务。此前，她曾担任好比拉医疗保健公司和礼来公司（Eli Lilly）的多种高级财务职务，包括礼来肿瘤公司的首席财务官。
- Barbara W. Bodem,was interim Chief Financial Officer of Dentsply Sirona Inc., a public dental equipment and supplies manufacturing company, from April 2022 to October 2022. Prior to that, she served as Senior Vice President and Chief Financial Officer of Hill-Rom Holdings, Inc., a medical device and medical technology provider, from 2018 until its acquisition by Baxter International Inc. in 2021. Earlier in her career, she served as Senior Vice President of Finance of Mallinckrodt Pharmaceuticals, a pharmaceutical manufacturer, from 2015 to 2018. She previously served in senior finance roles at Hospira, Inc. and Eli Lilly and Company.Ms. Bodem currently serves on the boards of Enovis Corp., a public medical technology company, and Option Care Health, Inc., a public provider of home and alternate site infusion services. She also serves on the boards of BiomEdit LLC, a private animal health company, NorthStar Medical Radioisotopes, a radiopharmaceutical company and the non-profit Nature Conservancy of Indiana. In the past five years, Ms. Bodem served on the boards of Syneos Health, Inc. and Turning Point Therapeutics, Inc. She also served on the board of Invacare Corporation.She holds a B.S. in Finance and an M.B.A from Indiana University.
- Amy Dodrill
Amy Dodrill当选为高级副总裁兼外科解决方案总裁，自2019年6月起生效。她此前曾担任我们美国外科手术解决方案销售业务的Vice President，在此之前，自2011年10月加入Hillrom以来，她曾担任我们患者支持系统业务的区域Vice President。加入Hillrom公司之前，她曾担任Dynavox Systems公司和GE梦百合公司的多种高级领导职务。
Amy Dodrill, was elected Senior Vice President and President, Surgical Solutions, effective June 2019. She had previously served as Vice President of U.S. Surgical Solutions sales operations and prior to that, as an area vice president in Patient Support Systems business since joining Hillrom in October 2011. Before joining Hillrom, she held several senior leadership roles at DynaVox Systems LLC and GE Healthcare.- Amy Dodrill当选为高级副总裁兼外科解决方案总裁，自2019年6月起生效。她此前曾担任我们美国外科手术解决方案销售业务的Vice President，在此之前，自2011年10月加入Hillrom以来，她曾担任我们患者支持系统业务的区域Vice President。加入Hillrom公司之前，她曾担任Dynavox Systems公司和GE梦百合公司的多种高级领导职务。
- Amy Dodrill, was elected Senior Vice President and President, Surgical Solutions, effective June 2019. She had previously served as Vice President of U.S. Surgical Solutions sales operations and prior to that, as an area vice president in Patient Support Systems business since joining Hillrom in October 2011. Before joining Hillrom, she held several senior leadership roles at DynaVox Systems LLC and GE Healthcare.
- Mary Kay Ladone
Mary Kay Ladone当选为高级副总裁，公司发展，战略和投资者关系，自2018年12月起生效。自2016年7月加入Hill-Rom以来，她曾担任投资者关系部Vice President。加入Hillrom公司之前，她曾担任Baxalta股份有限公司公司的投资者关系高级副总裁，。此前，她曾担任Baxter International公司的多种高级财务、业务开发和投资者关系职务。
Mary Kay Ladone,is an accomplished executive with over 35 years of experience serving large global healthcare companies. Ms. Ladone served as senior vice president of corporate development, strategy and investor relations at Hill-Rom Holdings, Inc. from 2018 to 2022, and vice president of investor relations at Hillrom from 2016 to 2018. Prior to Hillrom, Ms. Ladone served as senior vice president and corporate officer, investor relations of Baxalta, Inc., a global biopharmaceutical company, from 2015 to 2016. Ms. Ladone began her career in finance at Baxter International, Inc., and from 1988 to 2015 served in several progressive financial, operational and communication roles at Baxter International, Inc.. Ms. Ladone currently serves on the board of directors of Novanta Inc., Bioventus LLC and Inogen, Inc. Ms. Ladone received her B.B.A. degree in Finance and Business Economics, cum laude, from the University of Notre Dame.- Mary Kay Ladone当选为高级副总裁，公司发展，战略和投资者关系，自2018年12月起生效。自2016年7月加入Hill-Rom以来，她曾担任投资者关系部Vice President。加入Hillrom公司之前，她曾担任Baxalta股份有限公司公司的投资者关系高级副总裁，。此前，她曾担任Baxter International公司的多种高级财务、业务开发和投资者关系职务。
- Mary Kay Ladone,is an accomplished executive with over 35 years of experience serving large global healthcare companies. Ms. Ladone served as senior vice president of corporate development, strategy and investor relations at Hill-Rom Holdings, Inc. from 2018 to 2022, and vice president of investor relations at Hillrom from 2016 to 2018. Prior to Hillrom, Ms. Ladone served as senior vice president and corporate officer, investor relations of Baxalta, Inc., a global biopharmaceutical company, from 2015 to 2016. Ms. Ladone began her career in finance at Baxter International, Inc., and from 1988 to 2015 served in several progressive financial, operational and communication roles at Baxter International, Inc.. Ms. Ladone currently serves on the board of directors of Novanta Inc., Bioventus LLC and Inogen, Inc. Ms. Ladone received her B.B.A. degree in Finance and Business Economics, cum laude, from the University of Notre Dame.
- Andreas G. Frank
Andreas G. Frank，他于2022年4月加入公司。加入Dentsply Sirona之前，Frank先生曾担任Baxter International Inc前线护理总裁（2021年12月以来）。加入Baxter之前，他在Hill-Rom Holdings Inc.担任同一职位。此前在Hill-Rom担任的职务包括首席转型官和企业发展与战略高级副总裁。加入Hill-Rom之前，Frank先生曾担任Danaher Corporation的企业发展总监和业务发展副总裁。他曾在麦肯锡公司（McKinsey & Company）的公司财务和战略实践部门工作。Frank先生分别在德国Otto Beisheim管理学院和德克萨斯大学奥斯汀分校Red McCombs商学院获得工商管理和经济学硕士学位，并在德克萨斯大学获得工商管理硕士学位。
Andreas G. Frank,joined the Company in April 2022. Prior to joining Dentsply Sirona, Mr. Frank served as President, Front Line Care at Baxter International Inc since December 2021. Prior to Baxter he held the same position at Hill-Rom Holdings Inc. Prior roles at Hill-Rom included Chief Transformation Officer and Senior Vice President, Corporate Development and Strategy. Prior to joining Hill-Rom, Mr. Frank served as Director of Corporate Development and Vice President, Business Development, at Danaher Corporation. He previously worked in the Corporate Finance and Strategy practice at McKinsey & Company. Mr. Frank received his master's degrees in business administration and economics from the Otto Beisheim School of Management in Germany and the University of Texas at Austin, Red McCombs School of Business, respectively, and an MBA from The University of Texas.- Andreas G. Frank，他于2022年4月加入公司。加入Dentsply Sirona之前，Frank先生曾担任Baxter International Inc前线护理总裁（2021年12月以来）。加入Baxter之前，他在Hill-Rom Holdings Inc.担任同一职位。此前在Hill-Rom担任的职务包括首席转型官和企业发展与战略高级副总裁。加入Hill-Rom之前，Frank先生曾担任Danaher Corporation的企业发展总监和业务发展副总裁。他曾在麦肯锡公司（McKinsey & Company）的公司财务和战略实践部门工作。Frank先生分别在德国Otto Beisheim管理学院和德克萨斯大学奥斯汀分校Red McCombs商学院获得工商管理和经济学硕士学位，并在德克萨斯大学获得工商管理硕士学位。
- Andreas G. Frank,joined the Company in April 2022. Prior to joining Dentsply Sirona, Mr. Frank served as President, Front Line Care at Baxter International Inc since December 2021. Prior to Baxter he held the same position at Hill-Rom Holdings Inc. Prior roles at Hill-Rom included Chief Transformation Officer and Senior Vice President, Corporate Development and Strategy. Prior to joining Hill-Rom, Mr. Frank served as Director of Corporate Development and Vice President, Business Development, at Danaher Corporation. He previously worked in the Corporate Finance and Strategy practice at McKinsey & Company. Mr. Frank received his master's degrees in business administration and economics from the Otto Beisheim School of Management in Germany and the University of Texas at Austin, Red McCombs School of Business, respectively, and an MBA from The University of Texas.
- Richard M. Wagner
Richard M. Wagner，他一直担任公司的首席会计官（2022年8月以来）。他此前曾担任Hillrom的副总裁、首席会计官和公司总会计师，监督财务收尾流程、报告、控制合规流程和共享服务组织。他积极参与了多项收购的整合，领导了财务组织的运营改进，并与运营领导层合作实施全球流程。在2018年加入Hillrom之前，他曾担任CREE, Inc.的照明副总裁兼财务总监，领导照明部门，并领导对大型收购的财务分析流程和尽职调查的重新设计。在CREE任职之前，他曾担任dentspply Sirona的副总裁、公司财务总监，直到2017年，他在dentspply和Sirona合并的财务整合中发挥了重要作用。Wagner先生毕业于宾夕法尼亚州立大学会计学学士学位，是注册会计师。
Richard M. Wagner,has served as Chief Accounting Officer of the Company since August 2022. He previously served as the Vice President, Chief Accounting Officer and Corporate Controller at Hillrom overseeing the financial close process, reporting, control compliance processes and the shared services organization. He was heavily involved in integrating multiple acquisitions, leading operational improvements in the finance organization and partnering with operating leadership to implement global processes. Before joining Hillrom in 2018, he served as the Vice President and Controller, Lighting at CREE, Inc. he provided leadership for the lighting division and led the re-design of the financial analysis process and due diligence for large acquisitions. Prior to his tenure at CREE, he was the Vice President, Corporate Controller at Dentsply Sirona until 2017 where he was instrumental in the financial integration of the merger between Dentsply and Sirona. Mr. Wagner graduated with a B.S. in Accounting from Penn State University and is a CPA.- Richard M. Wagner，他一直担任公司的首席会计官（2022年8月以来）。他此前曾担任Hillrom的副总裁、首席会计官和公司总会计师，监督财务收尾流程、报告、控制合规流程和共享服务组织。他积极参与了多项收购的整合，领导了财务组织的运营改进，并与运营领导层合作实施全球流程。在2018年加入Hillrom之前，他曾担任CREE, Inc.的照明副总裁兼财务总监，领导照明部门，并领导对大型收购的财务分析流程和尽职调查的重新设计。在CREE任职之前，他曾担任dentspply Sirona的副总裁、公司财务总监，直到2017年，他在dentspply和Sirona合并的财务整合中发挥了重要作用。Wagner先生毕业于宾夕法尼亚州立大学会计学学士学位，是注册会计师。
- Richard M. Wagner,has served as Chief Accounting Officer of the Company since August 2022. He previously served as the Vice President, Chief Accounting Officer and Corporate Controller at Hillrom overseeing the financial close process, reporting, control compliance processes and the shared services organization. He was heavily involved in integrating multiple acquisitions, leading operational improvements in the finance organization and partnering with operating leadership to implement global processes. Before joining Hillrom in 2018, he served as the Vice President and Controller, Lighting at CREE, Inc. he provided leadership for the lighting division and led the re-design of the financial analysis process and due diligence for large acquisitions. Prior to his tenure at CREE, he was the Vice President, Corporate Controller at Dentsply Sirona until 2017 where he was instrumental in the financial integration of the merger between Dentsply and Sirona. Mr. Wagner graduated with a B.S. in Accounting from Penn State University and is a CPA.
- John P. Groetelaars
John P. Groetelaars在2008年加入 Bard 在Davol部门担任副总裁和总经理。在2009年Mr. Groetelaars 被提名为Davol部总裁。在2013年七月，Mr. Groetelaars晋升为集团副总裁和负责中国、亚洲、澳大利亚的特别小组，继续负责 Bards Davol部门。在加入Bard之前，他担任了多种职务，包括从2001年至加入Bard公司之前负责波士顿科学公司事务，在英国、爱尔兰和北欧地区担任总经理和副总裁。
John P. Groetelaars served as President & Chief Executive Officer and as a director of Hill-Rom Holdings, Inc. from May 14 2018 until the company’s acquisition by Baxter International, Inc. in December 2021. At Hillrom, Mr. Groetelaars had enterprise responsibility for a global healthcare technology company with $3 billion in revenue and more than 10000 employees. Mr. Groetelaars led a transformation of Hillrom’s business, successfully articulating and launching a new connected-care strategy and vision, growing the portfolio through seven acquisitions and one divestiture, and driving record financial performance. In addition, he championed and actively led diversity, inclusion, equity and belonging initiatives across the company, which led to record levels of employee engagement, and external recognition from DiversityInc, Forbes and many other organizations. Prior to Hill-Rom, Mr. Groetelaars served as executive vice president and president of the Interventional Segment at Becton, Dickinson and Company, a medical technology company, since December 2017 following its acquisition of C.R. Bard Inc., a medical technology company, where his responsibilities included global strategic, financial, operational and innovation platforms. He previously served in a variety of progressive roles at C.R. Bard during his 10-year career there, including as a group president from 2015 to 2017. Mr. Groetelaars joined C.R. Bard in 2008 as vice president and general manager, Davol Inc., and was appointed president of Davol in 2009. In 2013 Mr. Groetelaars was promoted to group vice president and in 2015 he was promoted to group president, a position he held until C.R. Bard was acquired by Becton, Dickinson and Company in December 2017. Prior to joining C.R. Bard, Mr. Groetelaars held various international leadership positions in Canada, Denmark and the United Kingdom at Boston Scientific Corporation from 2001 until 2008. Prior to joining Boston Scientific, Mr. Groetelaars held positions in general management, marketing, business development and sales with Guidant Corporation and with Eli Lilly. He was also formerly a director on the AdvaMed board.- John P. Groetelaars在2008年加入 Bard 在Davol部门担任副总裁和总经理。在2009年Mr. Groetelaars 被提名为Davol部总裁。在2013年七月，Mr. Groetelaars晋升为集团副总裁和负责中国、亚洲、澳大利亚的特别小组，继续负责 Bards Davol部门。在加入Bard之前，他担任了多种职务，包括从2001年至加入Bard公司之前负责波士顿科学公司事务，在英国、爱尔兰和北欧地区担任总经理和副总裁。
- John P. Groetelaars served as President & Chief Executive Officer and as a director of Hill-Rom Holdings, Inc. from May 14 2018 until the company’s acquisition by Baxter International, Inc. in December 2021. At Hillrom, Mr. Groetelaars had enterprise responsibility for a global healthcare technology company with $3 billion in revenue and more than 10000 employees. Mr. Groetelaars led a transformation of Hillrom’s business, successfully articulating and launching a new connected-care strategy and vision, growing the portfolio through seven acquisitions and one divestiture, and driving record financial performance. In addition, he championed and actively led diversity, inclusion, equity and belonging initiatives across the company, which led to record levels of employee engagement, and external recognition from DiversityInc, Forbes and many other organizations. Prior to Hill-Rom, Mr. Groetelaars served as executive vice president and president of the Interventional Segment at Becton, Dickinson and Company, a medical technology company, since December 2017 following its acquisition of C.R. Bard Inc., a medical technology company, where his responsibilities included global strategic, financial, operational and innovation platforms. He previously served in a variety of progressive roles at C.R. Bard during his 10-year career there, including as a group president from 2015 to 2017. Mr. Groetelaars joined C.R. Bard in 2008 as vice president and general manager, Davol Inc., and was appointed president of Davol in 2009. In 2013 Mr. Groetelaars was promoted to group vice president and in 2015 he was promoted to group president, a position he held until C.R. Bard was acquired by Becton, Dickinson and Company in December 2017. Prior to joining C.R. Bard, Mr. Groetelaars held various international leadership positions in Canada, Denmark and the United Kingdom at Boston Scientific Corporation from 2001 until 2008. Prior to joining Boston Scientific, Mr. Groetelaars held positions in general management, marketing, business development and sales with Guidant Corporation and with Eli Lilly. He was also formerly a director on the AdvaMed board.
- Paul Johnson
Paul Johnson，自2013年10月以来，一直担任我们销售和服务部的执行副总裁。从2013年8月至2013年10月，Johnson先生担任Digital Insight公司的销售副总裁，这是一家在线和移动银行解决方案的供应商。从2011年1月至2013年8月，Johnson先生担任Intuit金融服务部门的销售和关系管理（Sales and Relationship Management at Intuit’s Financial Services Division，在2013年8月改为Digital Insight following Intuit’s sale）的副总裁。从2007年11月到2010年12月，他担任 Sage Software, Inc.的北美软件业务解决方案的执行副总裁，这是一家提供企业管理软件及服务的公司。此外，Johnson先生曾在International Business Machines Corporation担任各种销售和服务职位。Johnson先生从南加州大学（the University of Southern California）获得了工商管理学士学位和硕士学位。
Paul Johnson, was elected as Senior Vice President and President of Patient Support Systems, effective November 2016. He had previously served as President, PSS North America, since joining Hillrom in February 2013. Before joining Hillrom, he held various commercial leadership positions at Life Technologies and GE Healthcare.- Paul Johnson，自2013年10月以来，一直担任我们销售和服务部的执行副总裁。从2013年8月至2013年10月，Johnson先生担任Digital Insight公司的销售副总裁，这是一家在线和移动银行解决方案的供应商。从2011年1月至2013年8月，Johnson先生担任Intuit金融服务部门的销售和关系管理（Sales and Relationship Management at Intuit’s Financial Services Division，在2013年8月改为Digital Insight following Intuit’s sale）的副总裁。从2007年11月到2010年12月，他担任 Sage Software, Inc.的北美软件业务解决方案的执行副总裁，这是一家提供企业管理软件及服务的公司。此外，Johnson先生曾在International Business Machines Corporation担任各种销售和服务职位。Johnson先生从南加州大学（the University of Southern California）获得了工商管理学士学位和硕士学位。
- Paul Johnson, was elected as Senior Vice President and President of Patient Support Systems, effective November 2016. He had previously served as President, PSS North America, since joining Hillrom in February 2013. Before joining Hillrom, he held various commercial leadership positions at Life Technologies and GE Healthcare.